中医药干预COVID-19肺炎动物模型的探讨Discussion of the Animal Models for Intervention of Traditional Chinese Medicine on COVID-19
潘卫松;张婷;刘海鑫;陈蓉;
PAN Weisong;ZHANG Ting;LIU Haixin;CHEN Rong;Wuhan Institute for Drug and Medical Devices Control;National Medical Products Administration Key Laboratory of Quality Research and Control of Pharmaceutical Preparations;Murad Research Center for Modernized Chinese Medicine,Institute of interdisciplinary integrative medicine research,Shanghai University of Traditional Chinese Medicine;
摘要(Abstract):
目的 阐明中医药有效防止新型冠状病毒肺炎(COVID-19)患者转化为危重症的作用机制,为建立中医药治疗COVID-19生物评价平台建立应用基础。方法 综述了近年来报道的COVID-19动物模型和病理生理研究进展。结果 发现直接用冠状病毒感染的动物模型均不易转化为重症甚至濒死症状,且存在生物安全风险,而用脂多糖(LPS)诱导的急性肺损伤模型与COVID-19患者的临床危重症病理生理反应较为接近。结论 脂多糖(LPS)诱导的大鼠急性肺损伤模型是现阶段对于中医药防治COVID-19进行研究较为理想的动物模型。
OBJECTIVE To clarify the mechanism of Chinese medicine to effectively prevent the transformation of COVID-19 patients into critical illness, and to establish an application basis for the establishment of a biological evaluation platform for the treatment of COVID-19 by Chinese medicine. METHODS This review summarized the research progress in animal models and pathophysiology of COVID-19 reported in recent years. RESULTS It was found that the animal models directly infected with coronavirus were not easily transformed into severe or even moribund symptoms, and had biosafety risks, while the acute lung injury model induced by lipopolysaccharide(LPS) was similar to the clinical pathophysiology of hospitalized patients with COVID-19.The pathophysiological reaction was relatively closed. CONCLUSION The rat model of acute lung injury induced by lipopolysaccharide(LPS) is an ideal animal model for the research on the prevention and treatment of COVID-19 by traditional Chinese medicine at this stage.
关键词(KeyWords):
新冠肺炎;新冠肺炎病毒;脂多糖(LPS);Toll样受体(TLR);动物模型,生物评价
COVID-19;SARS-CoV-2;lipopolysaccharide(LPS);Toll-like receptor(TLR);animal model,biological evaluation
基金项目(Foundation): 湖北省药品监督管理局科研项目(20200103)
作者(Authors):
潘卫松;张婷;刘海鑫;陈蓉;
PAN Weisong;ZHANG Ting;LIU Haixin;CHEN Rong;Wuhan Institute for Drug and Medical Devices Control;National Medical Products Administration Key Laboratory of Quality Research and Control of Pharmaceutical Preparations;Murad Research Center for Modernized Chinese Medicine,Institute of interdisciplinary integrative medicine research,Shanghai University of Traditional Chinese Medicine;
参考文献(References):
- [1] 杨安辉,刘宇灵,林龙飞,等.清热解毒类中药抗新型冠状病毒肺炎研究进展[J].中华中医药学刊,2021,39(1):181-186.
- [2] 金江炜,施建荣,蔡建,等.中药治疗新型冠状病毒肺炎临床研究文献的质量评价[J].药学实践杂志,2021,39(3):206-210.
- [3] 杨钧婷,王晓堂,续国强,等.新型冠状病毒肺炎动物模型的研究进展[J].中国比较医学杂志,2020,30(9):111-116.
- [4] 白亮,刘宝宁,赵四海,等.新型冠状病毒来源、传播途径及易感动物模型研究进展[J].临床医学研究与实践,2020,5(1):1-2,11.
- [5] 包蕾,时宇静,耿子涵,等.热炎宁合剂在评价人冠状病毒肺炎疫毒袭肺证中的应用[J].中国中药杂志,2020,45(7):1465-1472.
- [6] 孙静,赵荣华,郭姗姗,等.苦参碱氯化钠注射液对人冠状病毒肺炎寒湿疫毒袭肺证小鼠病证结合模型的治疗作用[J].药学学报,2020,55(3):366-373.
- [7] 郭姗姗,李丹,时宇静,等.基于冠状病毒肺炎寒湿疫毒袭肺证病证结合模型的金柴抗病毒胶囊疗效评价[J].中国实验方剂学杂志,2020,26(13):1-7.
- [8] 鲍岩岩,时宇静,郭姗姗,等.复方芩兰口服液对人冠状病毒肺炎疫毒袭肺证的治疗作用[J].中国中药杂志,2020,45(7):1473-1480.
- [9] 孙静,赵荣华,包蕾,等.热毒宁注射液不同给药途径对幼龄小鼠副流感病毒肺炎的药理作用[J].世界中医药,2021,16(16):2423-2426.
- [10] 赵荣华,孙静,郭姗姗,等.体外培育牛黄对人冠状病毒肺炎疫毒袭肺证小鼠病证结合模型的效用特点[J].中国实验方剂学杂志,2021,27(2):66-73.
- [11] 赵荣华,郭姗姗,耿子涵,等.柴银颗粒对人冠状病毒肺炎湿热疫毒袭肺小鼠病证结合模型治疗及作用机制研究[J].中国药物警戒,2021,18(12):1123-1128,1154.
- [12] 郭姗姗,赵荣华,耿子涵,等.清开灵注射液治疗冠状病毒肺炎的作用机制研究[J].中国药物警戒,2021,18(12):1111-1116.
- [13] 冯小丽,李明华,韩建保,等.动物生物安全三级实验室内新型冠状病毒实验活动的防护措施探讨[J].赣南医学院学报,2021,41(9):909-914.
- [14] 刘婷,孔子月.国家生物安全实验室的法律规制——基于生物安全的双重含义[J].实验室研究与探索,2021,40(8):297-303.
- [15] 李洁,韩俊.医学病毒学生物安全三级动物实验室的建立[J].病毒学报,2021,37(6):1440-1447.
- [16] 王明翠,赵海峰.实验室生物安全突发事件应急办法及建议[J].质量安全与检验检测,2021,31(4):82-83.
- [17] 罗银珠,闵凡贵,王静,等.病原微生物防控在实验动物设施管理与生物安全控制中的作用探讨[J].实验动物与比较医学,2021,41(5):443-449.
- [18] 张艳丽,蒋澄宇.Cytokinestorm in ARDS[J].生命科学,2015,27(5):554-557.
- [19] Soy M,Keser G,Atagündüz P,et al.Cytokine storm in COVID-19:pathogenesis and overview of anti-inflammatory agents used in treatment[J].Clinical Rheumatology,2020,39(7):2085-2094.
- [20] Hu B,Huang S,Yin L.The cytokine storm and COVID-19.J Med Virol.2021;93(1):250-6.
- [21] Luo X H,Zhu Y,Mao J,et al.T cell immunobiology and cytokine storm of COVID-19[J].Scand J Immunol,2021,93(3):e12989.
- [22] Kumar H,Kawai T,Akira S.Toll-like receptors and innate immunity[J].Biochem Biophys Res Commun,2009,388(4):621-625.
- [23] 马成瑶,刘振东,张彦龙.凝集素与TLRs信号通路的免疫调节作用[J].食品工业科技,2019,40(24):355-360.
- [24] Imai Y,Kuba K,Neely G G,et al.Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury[J].Cell,2008,133(2):235-249.
- [25] Cao C,Yin C,Shou S,et al.Ulinastatin Protects Against LPS-Induced Acute Lung Injury By Attenuating TLR4/NF-κB Pathway Activation and Reducing Inflammatory Mediators[J].Shock,2018,50(5):595-605.
- [26] 李宏,马宁.乌司他丁减轻新型冠状病毒肺炎(COVID-19)重症患者肺损伤的可行性[J].药物评价研究,2020,43(5):959-963.
- [27] 马静,张鑫,张立朋.乌司他丁在新型冠状病毒肺炎治疗中的作用探析[J].武警后勤学院学报(医学版),2020,29(6):70-73,84.
- [28] 李微,盛云华,航艾,等.气管内雾化脂多糖致大鼠肺部炎症损伤模型研究[J].中国药学杂志,2017,52(6):457-461.
- [29] 成果,廖瑛,周君,等.脂多糖诱导大鼠吸入性肺炎动物模型的建立[J].中国预防医学杂志,2019,20(5):396-399.
- [30] 唐思璇,肖芳.脂多糖诱导肺炎动物模型的研究进展[J].中国实验动物学报,2020,28(6):864-869.
- 新冠肺炎
- 新冠肺炎病毒
- 脂多糖(LPS)
- Toll样受体(TLR)
- 动物模型,生物评价
COVID-19 - SARS-CoV-2
- lipopolysaccharide(LPS)
- Toll-like receptor(TLR)
- animal model,biological evaluation
- 潘卫松
- 张婷
- 刘海鑫
- 陈蓉
PAN Weisong- ZHANG Ting
- LIU Haixin
- CHEN Rong
- Wuhan Institute for Drug and Medical Devices Control
- National Medical Products Administration Key Laboratory of Quality Research and Control of Pharmaceutical Preparations
- Murad Research Center for Modernized Chinese Medicine
- Institute of interdisciplinary integrative medicine research
- Shanghai University of Traditional Chinese Medicine
- 潘卫松
- 张婷
- 刘海鑫
- 陈蓉
PAN Weisong- ZHANG Ting
- LIU Haixin
- CHEN Rong
- Wuhan Institute for Drug and Medical Devices Control
- National Medical Products Administration Key Laboratory of Quality Research and Control of Pharmaceutical Preparations
- Murad Research Center for Modernized Chinese Medicine
- Institute of interdisciplinary integrative medicine research
- Shanghai University of Traditional Chinese Medicine